{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Nounu A"],"funding":["Cancer Research UK","NCATS NIH HHS","NIA NIH HHS","NIEHS NIH HHS","Regional Council of Pays de la Loire","NHLBI NIH HHS","National Institute on Aging","European Research Council","U.S. Department of Health and Human Services","Ontario Research Fund","NIH HHS","WHI NIH HHS","Intramural NIH HHS","UK Medical Research Council Integrative Epidemiology Unit","World Health Organization","NIH","The Johns Hopkins University","Early Detection Research Network","NCI","NIDDK NIH HHS","Medical Research Council","Bowel Cancer UK","NHGRI NIH HHS","NCI NIH HHS","MRC Research","Hospital Clinical Research Program","Wellcome Trust"],"pagination":["564-575"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8086774"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(3)"],"pubmed_abstract":["<h4>Background</h4>Evidence for aspirin's chemopreventative properties on colorectal cancer (CRC) is substantial, but its mechanism of action is not well-understood. We combined a proteomic approach with Mendelian randomization (MR) to identify possible new aspirin targets that decrease CRC risk.<h4>Methods</h4>Human colorectal adenoma cells (RG/C2) were treated with aspirin (24 hours) and a stable isotope labeling with amino acids in cell culture (SILAC) based proteomics approach identified altered protein expression. Protein quantitative trait loci (pQTLs) from INTERVAL (<i>N</i> = 3,301) and expression QTLs (eQTLs) from the eQTLGen Consortium (<i>N</i> = 31,684) were used as genetic proxies for protein and mRNA expression levels. Two-sample MR of mRNA/protein expression on CRC risk was "],"journal":["Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"],"pubmed_title":["A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer."],"pmcid":["PMC8086774"],"funding_grant_id":["U01 CA137088","19PT0039","K05 CA154337","U01 CA074783","K05 CA152715","R01 CA143247","C18281/A19169;","HHSN268201100001I","R01 CA072520","R37 CA054281","HHSN268201100001C","U01 HG004438","MC_UU_12013_2","U01 CA122839","R01 CA081488","R01 CA81488","P01 CA033619","P30 CA016058","001","MR/R017247/1;","HHSN268201100002I","R01 CA136726","HHSN268201100002C","C18281/A19169","19169","U01 CA084968","U24 CA074783","19167","K07 CA190673","HHSN268201100003C","HHSN268201700006C","MC_UU_12013/2","UM1 CA167552","U01 CA067941","P30 DK034987","S10 OD028685","P01 CA055075","U01 CA86308","HHSN268201100003I","R01 CA059045","232997","U01 CA164930","U19 CA148107","U24 CA074794","29019","HHSN268201100004C","R01 CA066635","R03 CA153323","217487/Z/19/Z","R01201407","HHSN268201100004I","UM1 CA182883","11975","U01 AG018033","P01 CA087969","R01 CA197350","KL2 TR000421","R21 CA191312","P30 CA014089","R01 CA151993","P30 CA076292","R01 CA076366","16561","P30 CA006973","G1000143","R01 CA207371","R01 CA137178","19PT0039;","R01 CA042182","217487/Z/19/Z;","R01 CA063464","R01 CA067941","P50 CA127003","MR/R017247/1","HHSN268201100046C","UM1 CA186107","112746","U01 CA086308","R35 CA197735","U01 AG18033","U01 HG004446","P30 CA008748","U01 CA167552","R01 CA048998","T32 ES013678","U01 CA167551","R01 CA189184","Z01 CP010200","HHSN268201200008I","C19/A11975;","R01 CA097325","HHSN268201200008C","MC_UU_00011/4","U01 CA164973","R01 CA201407","P30 CA015704","U01 CA074794","U01 CA206110","HHSN271201100004C","PHRC-BRD09/C","U10 CA037429"],"pubmed_authors":["Richmond RC","Bishop DT","Bermejo JL","Lin Y","Berndt SI","Schoen RE","Pharoah PDP","Le Marchand L","Castellvi-Bel S","Li CI","Peters U","Slattery ML","Ulrich CM","Gunter MJ","Wolk A","Baron JA","Chang-Claude J","Greenhough A","Relton CL","Zheng W","Van Guelpen B","Kweon SS","Li L","Scherer D","Figueiredo JC","Gruber SB","van Duijnhoven FJB","Brenner H","Gsur A","Sakoda LC","Hoffmeister M","Heesom KJ","Woods MO","Drew DA","Williams AC","Platz EA","Weinstein SJ","Zheng J","Keku TO","Schafmayer C","Gallinger S","Giles GG","White E","Casey G","Newcomb PA","Buchanan DD","Stadler ZK","Hampel H","Chan AT","Lindor NM","Nounu A","Vodicka P","Lindblom A","Kim HR","Rennert G","Albanes D","Hopper JL","Harrison TA","Campbell PT","Moreno V","Vodickova L","Wu AH"],"additional_accession":[]},"is_claimable":false,"name":"A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer.","description":"<h4>Background</h4>Evidence for aspirin's chemopreventative properties on colorectal cancer (CRC) is substantial, but its mechanism of action is not well-understood. We combined a proteomic approach with Mendelian randomization (MR) to identify possible new aspirin targets that decrease CRC risk.<h4>Methods</h4>Human colorectal adenoma cells (RG/C2) were treated with aspirin (24 hours) and a stable isotope labeling with amino acids in cell culture (SILAC) based proteomics approach identified altered protein expression. Protein quantitative trait loci (pQTLs) from INTERVAL (<i>N</i> = 3,301) and expression QTLs (eQTLs) from the eQTLGen Consortium (<i>N</i> = 31,684) were used as genetic proxies for protein and mRNA expression levels. Two-sample MR of mRNA/protein expression on CRC risk was ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2026-05-09T00:39:12.302Z","creation":"2022-02-11T10:05:09.46Z"},"accession":"S-EPMC8086774","cross_references":{"pubmed":["33318029"],"doi":["10.1158/1055-9965.epi-20-1176","10.1158/1055-9965.EPI-20-1176"]}}